

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043641 A1

(51) International Patent Classification: **A61K 31/663**,
31/734

(21) International Application Number: PCT/TR02/00055

(22) International Filing Date: 15 October 2002 (15.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2001/03166 19 November 2001 (19.11.2001) TR

(71) Applicant (for all designated States except US): NOBEL
ILAÇ SANAYİ VE TİCARET A.Ş. [TR/TR]; Barbaros
Bulvarı 76-78, Beşiktaş, 80692 İstanbul (TR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): USLU, Abdullah
[TR/TR]; Barbaros Bulvarı 76-78, Beşiktaş, 80692 İstanbul (TR).

(74) Agent: KAYACAN, Vildan; Portakal Çiçeği Sok. No:5/1,
A. Ayrancı, 06690 Ankara (TR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/043641 A1

(54) Title: NEW PHARMACEUTICAL COMBINATIONS PREPARED WITH ALGINATES AND BIPHOSPHONATES IN ORDER TO PREVENT GASTROESOPHAGEAL REFLUX DURING USE OF ORAL BIPHOSPHONATES

(57) Abstract: This invention is about a method for preparation of pharmaceutical composition which contains biphosphonate derivation in such quantity to reduce loss of calcium in the bone tissue to prevent gastroesophageal reflux which occurs during use of oral biphosphonates and anti-reflux agent in such quantity to prevent gastroesophageal reflux of this biphosphonate derivation. Alginic acid and/or its salts, preferably alginic acid or sodium alginate, are used as anti-reflux agent.

DESCRIPTION

NEW PHARMACEUTICAL COMBINATIONS PREPARED WITH ALGINATES
AND BIPHOSPHONATES IN ORDER TO PREVENT GASTROESOPHAGEAL
5 REFLUX DURING USE OF ORAL BIPHOSPHONATES.

This invention is about a method for preparation of a pharmaceutical composition that contains a biphosphonate derivative in a quantity to reduce loss of calcium from the bone tissue and an anti-reflux agent in a quantity to be effective in prevention of
10 gastroesophageal reflux of this biphosphonate derivative.

Biphosphonates are synthetic analogs of pyrophosphate bonded to hydroxyapatite present in the bone tissue. They are effective in prevention and treatment of cases when the mineral content of bone reduces through inhibition of osteoclasts, which are the cells responsible for bone resorption.

15

Osteoporosis is a term indicating reduction in the bone mass and density related to the age and metabolic disturbances. This problem generally affects post-menopausal women and elderly men. The most common clinical cases that occur related to osteoporosis are occurrence of fractures at vertebra, bones at hip and wrist. Currently a number of
20 therapies are used and tried for solution of this problem. Development of osteoporosis is prevented, or if it is established, treated by means of Calcium and Vitamin D supplement, physical activity, selective estrogen-receptor modulators, phytoestrogens, medical products such as calcitonin, biphosphonates such as alendronate, etidronate and risedronate.

25

Biphosphonates are also used in other clinical indications such as Paget's disease, heterotrophic ossification, hypercalcemia developed in connection with malign diseases, bone metastases which originate from malign tumors.

30 Common adverse effects of biphosphonates are that they cause severe gastric and esophageal disturbances. Pharmacologic characteristics and adverse effects of biphosphonates are detailed in Physician's Desk Reference 55. edition, 2001, "Upper Gastrointestinal Toxicity of Alendronate" The American Journal of Gastroenterology

2000, "Oral Bisphosphonates: A review of clinical use in patients with bone metastases"
Cancer, January 1, 2000, Volume 88, Number 1, 6-14.

5 Reflux esophagitis occurs with passage of gastric fluid in small quantities or food or
bile acids or substances with irritant characteristic present in the gastric content and an
~~in the regions outside the gastric mucosa into the lower part of esophagus. Such types of~~
contents cause important implications resulting in inflammation in the esophageal
mucosa.

10 In order to prevent occurrence of these adverse effects, it is aimed at accelerating
passage of the drug with one glass of water into the stomach and it is recommended that
patients should not lie and rest on bed till first food of the day for at least 30 minutes in
order to prevent reflux of the drug from stomach to esophagus. Furthermore, it is
recommended that the drug should not be taken before going to bed or before rising up
15 from the bed in the morning. It is stated that these recommendations are for keeping risk
of the occurrence of adverse effects related to esophagus in connection with the drug to
the minimum extent.

In WO 98/25628, in order to reduce these risks, a new pharmaceutical composition has
been developed with alendronate sodium and active agent called cisapride that activates
20 gastric discharge.

Alginic acid has been discovered by E.C.C.Stanford, British pharmacist, in 1883.
Alginates may be different forms such as alginic acid and sodium, potassium,
magnesium, calcium, ammonium salt form of its.. Alginic acid and its salts are used for
25 treatment and prevention of esophageal reflux. These types of use of alginates are
described in WO patent 95/1168, WO patent 85/04806, WO patent 97/36599, WO
patent 01/66119.

This invention relates to a pharmaceutical composition that may prove to be useful in
30 prevention of reflux esophagitis that occur during bisphosphonate treatment, gastric
and/or peptic ulcerations and about pharmaceutical compositions that contains alginic
acid and/or one of its salts.

Esophageal and gastric disturbances have been considered as complications related to gastroesophageal reflux that is likely to appear in the patients under biphosphonate treatment. The aim of this invention is, therefore, to prepare a pharmaceutical composition of biphosphonate in effective quantity therapeutically and alginic acid
5 and/or alginic acid salts in effective quantity therapeutically in order to prevent gastroesophageal reflux of biphosphonates***.

Alendronate is a drug that prevents loss of calcium by inhibiting osteoclasts in the bone tissue pharmacologically. It is used for treatment of the established osteoporosis in the
10 post-menopausal women or for prevention of osteoporosis expected to develop during this period and treatment of osteoporosis developed in connection with glucocorticoid treatment and, finally, for treatment of Paget's disease. It has been launched Merck&Co. under the name of Fosamax®. This product may causes*** esophagitis due to gastric reflux. Recommended doses are 5 mg/day, 10 mg/day and 35 mg/week, 70 mg/week. It
15 is also used as 40mg/day over 6 months for Paget's disease.

Risedronate is a pyridinyl biphosphonate. It inhibits bone resorption generated by osteoclasts in the bone tissue and regulates bone metabolism. It was launched by Procter&Gamble under the name of Actonel®. This product may causes*** esophagitis
20 due to gastric reflux. Recommended dose for prevention and treatment of postmenopausal osteoporosis as well as osteoporosis connected to glucocorticoid is 5 mg/day. Furthermore, dose of 30 mg/day is used for Paget's disease for 2 months.

Etidronate is an agent, primarily active in the bone tissue. It inhibits formation, growth
25 and dissolution of hydroxyapatite crystals. It also inhibits chemisorption of amorphous precursors onto the calcium phosphate surface. It has been launched by Procter&Gamble under the name of Didronel®. Recommended dosage for Paget's disease is 5-10 mg/kg/day for a period upto 6 months and 11-20 mg/kg/day for a period upto 3 months. In the heterotrophic ossification it is started from 1 month before total Hip replacement
30 operation to 3 months afterwards. In these patients, the dose is 20 mg/kg/day. For patients with spinal cord trauma, it is administered 20 mg/kg/day for 2 weeks and later on it is administered by 10 mg/kg/day for 10 weeks.

Tiludronate prevents loss of calcium by inhibiting osteoclast activity in the bone tissue . It creates this effect possibly by suppressing enzymatic and transport factors that cause mineral matrix resorption. It has been launched by Sanofi Synthelabo Inc. under the name of Skelid®. Recommended dose for Paget's disease is 400 mg/day.

5

~~Alginic acid and its salts are used in various compositions for treatment and prevention of esophagual reflux. When alginic acid contacts with the gastric*** content, it causes a formation that floats over the gastric content. This foamy structure serves as a mechanical barrier preventing passage of the gastric content into the esophagus. With~~
10 prevention of reflux, the destructive effects of the irritant materials of the gastric content are eliminated.

This invention encompasses a pharmaceutical composition comprising an effective amount of biphosphonate derivatives for reducing calcium loss and effective amount of alginic acid and/or its salts to prevent gastroesophageal reflux.

15 In accordance with this invention, the active agents of the biphosphonate group and the alginates can be prepared in double-layer tablets or conventional tablets. Furthermore, alginates or active agent may be pressed in core tablet an the other part may be pressed onto it as a separate layer. Furthermore, the alginates and drugs of the biphosphonate group are also mixed and prepared in capsules. Preferablely, pharmaceutical composition
20 in double-layer tablet is prepared.

In the composition of double-layer tablet, alginic acid and/or its salts (sodium, potassium, magnesium, calcium, ammonium, etc.) and one of the active agents of the biphosphonate group are made into a double-layer tablet. Preparation of double-layer
25 tablet, after alginic acid and/or its salts (sodium, potassium, magnesium, calcium, ammonium, etc.) are prepared granules by wet granulation or not prepared granules (powder), these granules or powder are mixed excipients for tablet pressing. For wet granulation, polyvinylpyrrolidones (PVP), gelatin, starches(such as corn starch, potato starch), starch derivatives (such as pregelatinized starch), cellulose derivations
30 (hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, etc.) can be used as binder. Preferably, PVP, pregelatinized starch or low substitute hydroxyprypolcellulose are used. Binding concentrate may be between 1-50% of the alginate.

Preferably alginic acid and sodium alginate are used which are used between 1 mg to 2000 mg, preferably 500 mg. In the formulation filling excipients such as microcrystalline cellulose, lactose, starches are used. Preferably, microcrystalline cellulose is used between 10% and 200% of the alginate. In the formulation, lubricants and glidants such as stearic acid, magnesium stearate, talk, aerosil are also used.

Preferably, magnesium stearate and aerosil are used in the formulation.

Disintegrants such as croscarmellose sodium, sodium starch gluconate can be used to the formulation.

In the formulation of alginates, a carbonate source such as sodium bicarbonate, sodium carbonate, calcium carbonate can be used and thus when the alginate enters into stomach, it may be ensured to swell immediately, forming a foamy structure.

In this composition of double-layer tablet, the other layer is composed of one of biphosphonates. The active agent of the biphosphonate derivatives used is prepared granules by wet granulation or not prepared granules (powder) and then mixed with other excipients for tablet pressing. For wet granulation, polyvinylpyrrolidones (PVP), gelatin, starches (such as corn starch, potato starch), starch derivatives (such as pregelatinized starch), cellulose derivations (hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, etc.) can be used as binder. Preferably, PVP, pregelatinized starch or low substitute hydroxypropylcellulose are used. Binding concentrate may be between 1-50% of the biphosphonate. In the formulation filling excipients such as microcrystalline cellulose, lactose, starches are used. Preferably, microcrystalline cellulose is used between 10% and 1000% of the biphosphonates. In the formulation, lubricants and glidants such as stearic acid, magnesium stearate, talk, aerosil are also used. Preferably, magnesium stearate are used in the formulation.

Disintegrants having superior disintegrate characteristic such as croscarmellose sodium, sodium starch gluconate are also added to the formulation. Preferably, croscarmellose sodium is used in the formulation.

After alginates and biphosphonates are pressed into double-layer tablets, on the tablet machine capable of pressing two-layer tablet. From the alginates, preferably alginic acid and sodium alginate are used in doses between 1mg and 2000mg, preferably 500mg

Another type of formulation is that after alginates and biphosphonates are mixed together they are made into tablet or capsule. In this formulation, unlike from the double-layer tablet formulation, biphosphonates and alginates are mixed. From the alginates, preferably alginic acid and sodium alginate are used in doses between 1mg
5 and 2000mg, preferably 500mg. ~~**They have been granular with use of the above-~~
mentioned binders or powder and mixed with filling agents, disintegrants, lubricants and glidants and pressed in tablet or filled in capsules,

Instead of double-layer tablet machine, by attaching a special apparatus to the classic
10 tablet machine, first one of the biphosphonates or alginates are pressed as core tablet and then other substance that have not been pressed is pressed onto it as a second layer. The formulation here is same with that one in the double-layer tablet formulation.

15

20

25

30

CLAIMS:

- 1- An oral pharmaceutical dosage form comprising a safe and effective amount a biphosphonate derivative in such quantity to reduce loss of calcium content of the bone tissue and an anti-reflux agent in such quantity to be effective for prevention of gastroesophageal reflux of this biphosphonate derivative.
- 2- A dosage form according to Claim 1 where alginic acid and/or its salts (such as sodium, potassium, magnesium, calcium, ammonium) are used as anti-reflux agent.
- 3- A dosage form according to Claim 2 where preferably alginic acid or sodium alginate is used as antireflux agent.
- 4- A dosage form according to Claim 3 where alginic acid or sodium alginate between 1mg and 2000 mg, preferably 500 mg, is used.
- 5- A dosage form according to Claim 1 where biphosphonates that vary between 1mg and 1000mg are used.
- 6- A dosage form according to Claim 5 where preferably alendronate, risedronate, etidronate, tiludronate are used as biphosphonate.
- 7- A dosage form according to Claim 1 which is made by preparation of active agents of biphosphonate derivatives and alginates in double-layer tablet or normal tablet or made by pressing alginates or active agents in core tablet and other part being pressed thereon as a separate layer or prepared in capsule by mixing alginates and biphosphonate derivatives.
- 8- A dosage form according to Claim 7 which is prepared preferably in double-layer tablet.
- 9- A dosage form according to Claim 4 which is used powder or prepared granules by wet granulation and then these powder or granules are mixed with fillin agent, lubricants and glidants for pressing tablet.

10- A dosage form according to Claim 4 and 9 where preferably wet granulation method is used.

11- A dosage form according to Claim 4 and 9 where polyvinylpyrrolidones (PVP),
5 gelatin, starches (such as corn starch, potato starch), starch derivatives (such as pregelatinized starch), cellulose derivatives (hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, etc.) are used as binder for wet granulation.

10 12- A dosage form according to Claim 11 where preferably PVP, pregelatinized starch or low substitute hydroxypropylcellulose is used.

13- A dosage form according to Claim 11 where concentration of binders is between 1%-50 of alginate.

15

14- A dosage form according to Claim 5 where the active agent of biphosphonate group is made granules by wet granulation and then mixed with filling agents, lubricants and glidants or directly mixed with filling agents, lubricants and glidants without making any granulation to make it powder or granules ready for tablet pressing.

20

25

30

INTERNATIONAL SEARCH REPORT

Internat. I Application No

PCT/TR 02/00055

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/663 A61K31/734

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 25628 A (FUISZ TECHNOLOGIES LTD (US)) 18 June 1998 (1998-06-18) cited in the application claims page 2, line 25 -page 3, line 3	1-14
Y	GROEN DE P C ET AL: "ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 335, no. 14, 3 October 1996 (1996-10-03), pages 1016-1021, XP002056398 ISSN: 0028-4793 the whole document	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

13 March 2003

Date of mailing of the International search report

21/03/2003

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3018

Authorized officer

Cortés, J

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/TR 02/00055

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 85 04806 A (RORER INT OVERSEAS (US)) 7 November 1985 (1985-11-07) cited in the application abstract; claim 1	1-14
Y	MACONI G ET AL: "MULTIPLE ULCERATIVE ESOPHAGITIS CAUSED BY ALENDRONATE" AMERICAN JOURNAL OF GASTROENTEROLOGY, NEW YORK, NY, US, vol. 90, no. 10, 1995, pages 1889-1890, XP002056397 ISSN: 0002-9270 the whole document	1-14
Y	WO 97 36599 A (KROTKIEWSKI MARCIN (SE)) 9 October 1997 (1997-10-09) cited in the application abstract; claim 1	1-14

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No.

PCT/TR 02/00055

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9825628	A	18-06-1998	US 5773429 A 30-06-1998
		CA 2250221 A1 18-06-1998	
		EP 0938319 A1 01-09-1999	
		JP 2001508769 T 03-07-2001	
		WO 9825628 A1 18-06-1998	
WO 8504806	A	07-11-1985	AT 77750 T 15-07-1992
		AU 578690 B2 03-11-1988	
		AU 4233685 A 15-11-1985	
		CA 1259916 A1 26-09-1989	
		CN 85104754 A 10-12-1986	
		DE 3586281 D1 06-08-1992	
		DE 3586281 T2 10-12-1992	
		EP 0179858 A1 07-05-1986	
		ES 8706029 A1 16-08-1987	
		FR 2563108 A1 25-10-1985	
		JP 7064737 B 12-07-1995	
		JP 61501916 T 04-09-1986	
		WO 8504806 A1 07-11-1985	
		US 4869902 A 26-09-1989	
WO 9736599	A	09-10-1997	SE 507682 C2 06-07-1998
		AT 224197 T 15-10-2002	
		AU 2525397 A 22-10-1997	
		DE 69715625 D1 24-10-2002	
		EP 0910388 A1 28-04-1999	
		JP 2000507572 T 20-06-2000	
		PL 329152 A1 15-03-1999	
		RU 2193407 C2 27-11-2002	
		SE 9601219 A 30-09-1997	
		WO 9736599 A1 09-10-1997	